In Vitro & In Vivo Diagnostic Substances
Standard Industrial Classification: SIC 2835
Industry Insider Sentiment Analysis
The In Vitro & In Vivo Diagnostic Substances sector (SIC 2835) acts as a critical barometer for broader economic health. Our real-time monitoring reveals 2536 total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-04 23:30 | 2024-05-31 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $80.82 | 1,179 | $95,287 | 101,498 |
| 2024-06-04 00:30 | 2024-05-31 | AWH | Aspira Women's Health Inc. | Sandford Nicole | Director, Officer | BUY | $2.42 | 9,493 | $22,973 | 70,596 |
| 2024-06-03 23:30 | 2024-05-30 | LNTH | Lantheus Holdings, Inc. | Niedzwiecki Daniel | Officer | SELL | $79.86 | 12,873 | $1,028,038 | 80,244 |
| 2024-06-03 23:06 | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Heath-Chiozzi Margo | Officer | OPT+S | $34.07 | 38,719 | $1,319,156 | 7,094 |
| 2024-06-03 23:05 | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Martin Samuel Bates | Officer | OPT+S | $34.05 | 35,000 | $1,191,775 | 25,128 |
| 2024-06-03 23:04 | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Cavanaugh Sarah | Officer | OPT+S | $33.73 | 20,853 | $703,334 | 1,860 |
| 2024-06-03 23:04 | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Crowley Elizabeth | Officer | OPT+S | $33.64 | 38,597 | $1,298,384 | 9,074 |
| 2024-05-30 23:34 | 2024-05-28 | LNTH | Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | OPT+S | $79.19 | 18,373 | $1,454,989 | 23,340 |
| 2024-05-30 23:32 | 2024-05-28 | LNTH | Lantheus Holdings, Inc. | McHugh Julie | Director | SELL | $78.50 | 2,500 | $196,250 | 28,617 |
| 2024-05-21 00:00 | 2024-05-17 | IDXX | IDEXX LABORATORIES INC /DE | Claflin Bruce L. | Director | SELL | $540.80 | 200 | $108,160 | 161 |
| 2024-05-16 00:49 | 2024-05-13 | MYGN | MYRIAD GENETICS INC | DIAZ PAUL J | Director, Officer | SELL | $25.14 | 227,844 | $5,728,773 | 1,066,166 |
| 2024-05-16 00:48 | 2024-05-13 | MYGN | MYRIAD GENETICS INC | Newcomer Lee Nisley | Director | SELL | $25.30 | 6,200 | $156,860 | 66,650 |
| 2024-05-16 00:09 | 2024-05-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $76.89 | 341 | $26,219 | 62,898 |
| 2024-04-17 23:30 | 2024-04-15 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $61.24 | 341 | $20,883 | 63,239 |
| 2024-04-17 19:04 | 2024-04-17 | NEOG | NEOGEN CORP | Jones Douglas Edward | Officer | BUY | $12.36 | 10,000 | $123,590 | 46,131 |
| 2024-04-16 02:21 | 2024-04-11 | OCX | Insight Molecular Diagnostics Inc. | BROADWOOD PARTNERS, L.P. | 10% owner | BUY | $2.92 | 2,420,000 | $7,057,688 | 4,929,066 |
| 2024-04-15 13:04 | 2024-04-11 | OCX | Insight Molecular Diagnostics Inc. | Riggs Josh | Director, Officer | BUY | $2.95 | 3,390 | $10,001 | 3,505 |
| 2024-04-15 13:02 | 2024-04-11 | OCX | Insight Molecular Diagnostics Inc. | Arno Andrew | Director | BUY | $2.95 | 33,898 | $99,999 | 69,054 |
| 2024-04-11 18:40 | 2024-04-11 | NEOG | NEOGEN CORP | BOREL JAMES C | Director | BUY | $13.06 | 7,500 | $97,986 | 21,392 |
| 2024-04-10 23:18 | 2024-04-10 | NEOG | NEOGEN CORP | Naemura David H. | Officer | BUY | $12.51 | 12,500 | $156,321 | 30,040 |
| 2024-04-10 21:25 | 2024-04-10 | NEOG | NEOGEN CORP | ADENT JOHN EDWARD | Officer | BUY | $12.36 | 23,000 | $284,190 | 152,389 |
| 2024-03-19 23:30 | 2024-03-15 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | Officer | SELL | $60.00 | 20,000 | $1,200,000 | 113,749 |
| 2024-03-15 23:30 | 2024-03-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $60.48 | 341 | $20,624 | 63,204 |
| 2024-03-11 23:30 | 2024-03-07 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $61.96 | 18,023 | $1,116,705 | 103,357 |
| 2024-03-08 01:00 | 2024-03-06 | IDXX | IDEXX LABORATORIES INC /DE | POLEWACZYK JAMES F | Officer | OPT+S | $558.44 | 8,104 | $4,525,596 | 10,711 |
| 2024-03-08 01:00 | 2024-03-05 | IDXX | IDEXX LABORATORIES INC /DE | Vandebroek Sophie V. | Director | OPT+S | $562.98 | 1,404 | $790,427 | 1,216 |
| 2024-03-08 00:30 | 2024-03-05 | LNTH | Lantheus Holdings, Inc. | LENO SAM R | Director | OPT+S | $64.06 | 4,090 | $262,005 | 57,937 |
| 2024-03-07 01:15 | 2024-03-04 | LNTH | Lantheus Holdings, Inc. | LENO SAM R | Director | OPT+S | $65.42 | 22,389 | $1,464,749 | 57,937 |
| 2024-03-07 00:49 | 2024-03-04 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Stewart Richard Alistair | Director, Officer | BUY | $4.59 | 10,000 | $45,850 | 38,501 |
| 2024-03-07 00:43 | 2024-03-04 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Bencich John | Director, Officer | BUY | $4.59 | 10,000 | $45,850 | 76,724 |
| 2024-03-06 04:28 | 2024-03-04 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Director | SELL | $65.31 | 93,863 | $6,129,892 | 251,643 |
| 2024-03-06 00:10 | 2024-03-04 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | Officer | SELL | $32.99 | 2,297 | $75,778 | 81,571 |
| 2024-03-06 00:10 | 2024-03-04 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | Officer | SELL | $32.99 | 605 | $19,959 | 71,470 |
| 2024-02-28 00:21 | 2022-08-15 | TKNO | Alpha Teknova, Inc. | Grossman Paul David | Director | BUY | $5.37 | 9,212 | $49,504 | 9,212 |
| 2024-02-27 02:48 | 2024-02-23 | QDEL | QuidelOrtho Corp | Busky Joseph M | Officer | BUY | $46.36 | 2,150 | $99,663 | 2,150 |
| 2024-02-16 00:30 | 2024-02-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $55.31 | 341 | $18,861 | 58,403 |
| 2024-02-10 01:03 | 2024-02-08 | IDXX | IDEXX LABORATORIES INC /DE | FENNELL GEORGE | Officer | OPT+S | $573.87 | 8,198 | $4,704,558 | 6,712 |
| 2024-02-10 01:01 | 2024-02-07 | IDXX | IDEXX LABORATORIES INC /DE | MCKEON BRIAN P | Officer | OPT+S | $570.01 | 23,326 | $13,295,974 | 29,718 |
| 2024-02-10 01:00 | 2024-02-07 | IDXX | IDEXX LABORATORIES INC /DE | MAZELSKY JONATHAN JAY | Director, Officer | OPT+S | $572.61 | 12,000 | $6,871,319 | 79,247 |
| 2024-01-31 04:31 | 2024-01-26 | AWH | Aspira Women's Health Inc. | Sandford Nicole | Director, Officer | BUY | $0.00 | 2,400 | $0 | 61,103 |
| 2024-01-19 00:30 | 2024-01-16 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $56.01 | 341 | $19,099 | 58,744 |
| 2024-01-11 00:15 | 2024-01-08 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | Officer | SELL | $28.87 | 2,275 | $65,682 | 43,927 |
| 2024-01-06 00:51 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Director, Officer | SELL | $29.46 | 19,223 | $566,310 | 846,486 |
| 2024-01-06 00:50 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | Officer | SELL | $29.46 | 5,843 | $172,135 | 54,372 |
| 2024-01-06 00:50 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | Officer | SELL | $29.46 | 5,532 | $162,973 | 46,202 |
| 2024-01-06 00:49 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Goddard Glenn | Officer | SELL | $29.46 | 5,365 | $158,053 | 40,585 |
| 2024-01-06 00:46 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Hicks Derek | Officer | SELL | $29.46 | 3,877 | $114,216 | 36,987 |
| 2024-01-06 00:45 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | Officer | SELL | $29.46 | 3,805 | $112,095 | 51,474 |
| 2024-01-06 00:44 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | Officer | SELL | $29.50 | 4,608 | $135,954 | 40,845 |
| 2024-01-03 18:41 | 2024-01-02 | VNRX | VOLITIONRX LTD | Eight Corp Ltd | 10% owner | SELL | $0.90 | 20,000 | $18,000 | 298,419 |
Sector-Wide Insider Alpha
Analyzing insider movements across the In Vitro & In Vivo Diagnostic Substances sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2835) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in In Vitro & In Vivo Diagnostic Substances
Every transaction in the In Vitro & In Vivo Diagnostic Substances industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.